

**Alzheimer’s Agents – Anti-Amyloid Antibodies:
 Kisunla (donanemab-azbt)
 Leqembi (lecanemab-irmb)
 Effective 02/01/2025**

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Kisunla (donanemab-azbt) and Leqembi (lecanemab-irmb) are amyloid beta-directed antibodies indicated for the treatment of Alzheimer’s disease. Treatment with Kisunla or Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease.

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

OR

Authorization may be granted all of the following criteria are met:

Kisunla and Leqembi

1. Member has ONE of the following:
 - a. Mild cognitive impairment (MCI)
 - b. Mild dementia associated with Alzheimer’s disease (AD)
2. Prescriber is a neurologist or geriatrics specialist consult notes from a neurologist or geriatrics specialist are provided
3. Medical records documenting Apolipoprotein E ε4 genetic testing to evaluate risk of amyloid related imaging abnormalities (ARIA)
4. Medical records documenting confirmed evidence of clinically significant AD neuropathology based on ONE of the following:
 - a. Amyloid positron emission tomography (PET)
 - b. Cerebral spinal fluid (CSF) **biomarkers**
5. Member has had a brain magnetic resonance imaging (MRI) within the last 12 months
6. Medical records documenting baseline (within the last 3 months) cognitive function based on ONE of the following objective assessments:

- a. Mini Mental State Exam (MMSE) score of:
 - i. Leqembi: ≥ 22
 - ii. Kisunla: ≥ 20
 - b. Montreal Cognitive Assessment (MoCA) score of ≥ 15
 - c. Saint Louis University Mental Status Examination (SLUMS) score ≥ 16.1
7. Member does not have any conditions that would impact treatment (see Appendix)

Continuation of Therapy

Requests for reauthorization may be granted when all of the following criteria are met:

1. Member has achieved or maintained a positive clinical response to therapy
2. **Leqembi:** Provider attestation that MRI monitoring has been completed before the fifth, seventh, and fourteenth infusions, again after one year of treatment (i.e., prior to the 26th infusion) and then periodically guided by patient symptoms and prior MRI findings in accordance with the FDA approved label
Kisunla: Provider attestation that MRI monitoring has been completed before the second, third, fourth, and seventh infusions.
3. Medical charts showing clinical benefit or delay in disease progression as documented by ONE of the following (within the last 3 months):
 - a. Mini Mental State Exam (MMSE) score of:
 - i. Leqembi: ≥ 22
 - ii. Kisunla: ≥ 20
 - b. Montreal Cognitive Assessment (MoCA) score of ≥ 15
 - c. Saint Louis University Mental Status Examination (SLUMS) score ≥ 16.1
4. Member does not have any conditions that would impact treatment (see Appendix)

Limitations

1. Initial approvals will be granted for 6 months
2. Reauthorizations will be granted for 12 months.

Appendix

Conditions Impacting Leqembi Treatment:

1. Any medical or neurological condition, other than AD, that might be a contributing cause of the individual's cognitive impairment
2. History of transient ischemic attack (TIA), stroke, or seizures in the past year
3. Contraindications to brain MRI scanning (e.g., non-MRI compatible implants)
4. Evidence of other clinically significant lesions on brain MRI that indicate another cause of the individual's cognitive impairment
5. Uncontrolled bleeding disorder (including platelet count $< 50,000$ or INR > 1.5)
6. Use of anticoagulants and/or antiplatelet medications or concomitant use has been evaluated by physician
7. Any uncontrolled immunological disease or immunological disease requiring treatment with immunoglobulins, systemic monoclonal antibodies, systemic immunosuppressants, or plasmapheresis

Conditions Impacting Kisunla Treatment:

1. Significant neurological disease affecting the central nervous system other than AD
2. Serious conditions (e.g., cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic [other than AD], psychiatric, immunologic, or hematologic disease) that can impact analysis of results or shorten lifespan of patients to less than 24 months



3. Presence of ARIA-E (amyloid-related imaging abnormalities-edema) or ARIA-H (amyloid-related imaging abnormalities-cerebral microhemorrhage)

References

1. Alawode DOT, Fox NC, Zetterberg H, Heslegrave HJ. Alzheimer's disease biomarkers revisited from amyloid cascade hypothesis standpoint. *Front Neurosci*. 2022;16(837390):1-14.
2. Andrews JS, Desai U, Kirson NY, et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. *Alzheimers Dement*. 2019;5:354-363.
3. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: a review. *JAMA*. 2019;322(16):1589-1599.
4. Atri A. The Alzheimer's disease clinical spectrum diagnosis and management. *Med Clin N Am*.
5. CMS announces plan to ensure availability of new Alzheimer's drugs [press release on the internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; 2023 Jun 1 [cited 2023 Jun 16]. Available from: <https://www.cms.gov/newsroom/press-releases/cms-announces-plan-ensure-availability-new-alzheimers-drugs>.
6. Cummings J, Lee G, Nahed P, et al. Alzheimer's disease drug development pipeline: 2022. *Alzheimer's Dement*. 2022;8:e12295.
7. Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388:9-21.
8. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathic assessment of Alzheimer's disease. *Alzheimers Dement*. 2012;8(1):1-13.
9. Iqbal K, Liu F, Gong CX, et al. Tau in Alzheimer's Disease and related tauopathies. *Curr Alzheimer Res*. 2010;7(8): 656-664.
10. Kisunla (donanemab-azbt). [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2024.
11. Lansdall CJ, McDougall F, Butler LM, et al. Establishing clinically meaningful change on outcome assessments frequently used in trials with mild cognitive impairment due to Alzheimer's disease. *J Prev Alz Dis*; 2023;1(10):9-18.
12. Leqembi (lecanemab-irmb) [prescribing information]. Nutley, NJ: Eisai and Biogen; July 2023.
13. Mintun MA, Lo AC, Duggans Evans C, et al. Donanemab in early Alzheimer's disease. *N Engl J Med*. 2021;384(18):1691-1704.
14. Petersen RC. Mild cognitive impairment: Epidemiology, pathology, and clinical assessment. UpToDate Web site. Updated May 28, 2024. Accessed July 12, 2024.
15. Reardon S. FDA approves Alzheimer's drug lecanemab amid safety concerns. *Nature*. 2023;613(7943):227-228.
16. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature*. 2016;537:50-56.
17. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ2 randomized clinical trial. *JAMA*. 2023;330(6):512-527.
18. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer disease with lecanemab, anti-A β protofibril antibody. *Alzheimers Res Ther*. 2021;13(80):1-14.
19. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody. *Alzheimers Res Ther*. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.
20. VanDyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
21. Wang J, Logovinskiy V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. *J Neurol Neurosurg Psychiatry*. 2016;87:993-999.



22. Withington CG, Turner RS. Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer’s disease. *Front Neurol.* 2022;13:1-7.

Review History

10/11/2023 - Reviewed at October P&T, Effective 12/1/23

10/09/2024 – Reviewed and updated at October P&T. Added Kisunla to the policy. Removed “appropriate dosing” from initial and reauthorization criteria. Updated reauthorization criteria to include MRI monitoring parameters for Kisunla. Updated Appendix to include conditions that would impact Kisunla treatment. Effective 1/1/2025.

12/11/2025 – Reviewed and updated at December P&T. Updated MMSE score for Kisunla to 20 or higher. Effective 2/1/2025

